Zinco e doenças respiratórias virais: efeito na infecção do novo Coronavírus
Resumo
OBJETIVO: Descrever o efeito da suplementação com zinco em doenças respiratórias e sobre a infecção pelo novo coronavírus. METODOLOGIA: Trata-se de uma revisão integrativa que incluiu pesquisas realizadas com seres humanos, indexadas nas bases de dados Pubmed, Scopus e ScienceDirect. Após aplicação de critérios de inclusão e leitura de textos completos, 11 estudos foram incluídos nesta revisão. RESULTADOS: Nos estudos demonstraram que o zinco tem sido utilizado em pesquisas com doenças virais em adultos, destacando-se os resfriados comuns. Nessa condição clínica, foi demonstrado que o zinco promoveu a redução da duração dos sintomas e da severidade da doença. Em relação à doença do novo coronavírus, as pesquisas ainda são escassas. Em análise de estudo de caso foi referida melhora nos sintomas relacionados à doença, e em estudo observacional, zinco não esteve associado com modificação do risco da mortalidade hospitalar. CONSIDERAÇÕES FINAIS: A análise dos estudos incluídos nesta revisão indica que a suplementação com zinco promoveu diminuição da duração e gravidade de resfriados comuns. Quanto à covid-19, são necessários estudos controlados para demonstrar possíveis efeitos do zinco no manejo dessa doença.
Palavras-chave
Texto completo:
PDFReferências
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N. Engl. J. Med.2020,382(2020):692-4.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020,38:727-733.
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Disponível em: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 51, 2020c. Disponível em: .
World Health Organization. Advice on the use of masks in the context of COVID-19; 2020. Disponível em: < https://apps.who.int/iris/rest/bitstreams/1279750/retrieve>
Lythgoe MP, Middleton P. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends Pharmacol Sci. 2020;41(6):363-382.
Horby P, Shen Lim W, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020; Preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.
Arora NK, Das MK. COVID-19 vaccine development and the way forward. Indian J Public Health. 2020;64(Supplement):S108-S111.
World Health Organization. DRAFT landscape of COVID-19 candidate vaccines –
July 2020. Disponível em:
Sanna A, Firinu D, Zavattari P, Valera P. Zinc Status and Autoimmunity: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(1):68.
Souza MT, Silva MD, Carvalho R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo). 2010;8(1):102-106.
Mendes KDS, Silveira RCCP, Galvao CM. Uso de Gerenciador de Referências Bibliográficas na Seleção dos Estudos Primários em Revisão Integrativa. Texto contexto - enferm. 2019,28:20170204.
Galvão CM. Evidence hierarchies. Acta Paul Enferm. 2006;19. VI.
Stetler CB, Morsi D, Rucki S et al. Utilization-focused integrative reviews in a nursing service. Appl Nurs Res.1998;11(4):195-206.
Eby GA, Davis DR, Halcomb WW. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984;25(1):20-4.
Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tyrrell DA. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother. 1987;20(6):893-901.
Farr BM, Conner EM, Betts RF, Oleske J, Minnefor A, Gwaltney JM, Jr. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother. 1987;31(8):1183-7.
Godfrey JC, Conant Sloane B, Smith DS, Turco JH, Mercer N, Godfrey NJ. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res. 1992;20(3):234-46.
Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1996;125(2):81-8.
Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;133(4):245-52.
Turner RB, Cetnarowski WE. Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. Clin Infect Dis. 2000;31(5):1202-8.
Deloria-Knoll M, Steinhoff M, Semba RD, Nelson K, Vlahov D, Meinert CL. Effect of zinc and vitamin A supplementation on antibody responses to a pneumococcal conjugate vaccine in HIV-positive injection drug users: a randomized trial. Vaccine. 2006;24(10):1670-9.
Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. J Infect Dis. 2008;197(6):795-802.
Finzi E. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients. International Journal of Infectious Diseases. 2020.
Yao JS, Paguio JA, Dee EC, Tan HC, Moulick A, Milazzo C, et al. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study. Chest. 2020.
Ishida T. Zinc-induced Immune Anti-infective Activities of Bacteriolysis by Zn2+-binding Peptidoglycan Autolysins and Virucide by Zinc-finger Antiviral Proteins against Bacterial and Viral Infections: A review. Clin Res Immunol 2019;2(2):1-8.
Schappert SM. National Ambulatory Medical Care Survey: 1989 summary. Vital Health Stat 13 1992;(110):1–80.
Gwaltney JM, Jr, Hendley JO, Simon G, et al. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med 1966;275:1261–8.
Turner RB. The treatment of rhinovirus infections: progress and potential. Antiviral Res 2001;49:1–14.
Suara RO, Crowe JE., Jr Effect of zinc salts on respiratory syncytial virus replication. Antimicrob Agents Chemother 2004;48: 783–90.
Novick SG, Godfrey JC, Godfrey NJ, Wilder HR. How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action. Med Hypotheses. 1996;46(3):295-302.
Gammoh NZ, Rink L. Zinc in Infection and Inflammation. Nutrients. 2017;9(6):624.
Haase H., Rink L. Zinc signals and immune function. BioFactors. 2014;40:27–40.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92:479–490.
Overbeck S., Rink L., Haase H. Modulating the immune response by oral zinc supplementation: A single approach for multiple diseases. Arch. Immunol. Ther. Exp. 2008;56:15–30.
te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176.
Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. PLoS One. 2014;9(10):e109180.
Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42.
DOI: https://doi.org/10.26694/jcs_hu-ufpi.v3i1.11210
Apontamentos
- Não há apontamentos.
Indexado em:
Diretórios:
